These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 30111817)

  • 1. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
    PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
    La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
    PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
    Lu Y; Liu Y; Oeck S; Glazer PM
    Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
    Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Onda N; Nakamichi S; Hirao M; Matsuda K; Matsumoto M; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Sci; 2024 Aug; 115(8):2718-2728. PubMed ID: 38941131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
    PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
    J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
    Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
    Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
    Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
    Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
    Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.